Novel association patterns of cardiac remodeling markers in patients with essential hypertension and atrial fibrillation
Tóm tắt
Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) are essential for the cardiac extracellular matrix (ECM) remodeling. We investigated differences in serum levels of these markers between patients with atrial fibrillation (AF) and sinus rhythm (SR). Serum levels of MMP-2, MMP-3, MMP-9 and TIMP-1 were measured in 86 patients: 27 on SR without any AF history, 33 with paroxysmal and 26 with permanent AF. All subjects had essential hypertension, normal systolic function and no coronary artery disease. Patients with AF had higher MMP-2, MMP-3 and MMP-9 and lower TIMP-1 compared to SR subjects (all p < 0.001). Paroxysmal AF was associated with higher MMP-2 levels compared to permanent AF (p < 0.001). Matrix metalloproteinase-9 but not MMP-3 was higher in permanent compared to paroxysmal AF group (p < 0.001). Patients with AF had lower levels of TIMP-1 compared to those with SR while permanent AF subjects had lower TIMP-1 levels than those with paroxysmal AF (p < 0.001 for both comparisons). Lower TIMP-1 was the only independent factor associated with AF (OR: 0.259, 95%CI: 0.104-0.645, p = 0.004). In hypertensives, paroxysmal AF and permanent AF differ with respect to serum MMPs. Increased MMP-2 is associated with paroxysmal, whereas increased MMP-9 with permanent AF. Additionally, lower levels of TIMP-1 had a strong association with AF incidence.
Tài liệu tham khảo
van den Berg MP, van Gelder IC, van Veldhuisen DJ: Impact of atrial fibrillation on mortality in patients with chronic heart failure. Eur J Heart Fail. 2002, 4 (5): 571-575. 10.1016/S1388-9842(02)00094-6.
Sun H, Gaspo R, Leblanc N, Nattel S: Cellular mechanisms of atrial contractile dysfunction caused by sustained atrial tachycardia. Circulation. 1998, 98 (7): 719-727.
Allessie M, Ausma J, Schotten U: Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res. 2002, 54 (2): 230-246. 10.1016/S0008-6363(02)00258-4.
Brundel BJ, Henning RH, Kampinga HH, Van Gelder IC, Crijns HJ: Molecular mechanisms of remodeling in human atrial fibrillation. Cardiovasc Res. 2002, 54 (2): 315-324. 10.1016/S0008-6363(02)00222-5.
Rizos I, Tsiodras S, Rigopoulos AG, Dragomanovits S, Kalogeropoulos AS, Papathanasiou S, Sakadakis EA, Kremastinos DT: Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome. Cytokine. 2007, 40 (3): 157-164. 10.1016/j.cyto.2007.08.013.
Rizos I, Rigopoulos AG, Kalogeropoulos AS, Tsiodras S, Dragomanovits S, Sakadakis EA, Faviou E, Kremastinos DT: Hypertension and paroxysmal atrial fibrillation: a novel predictive role of high sensitivity C-reactive protein in cardioversion and long-term recurrence. J Hum Hypertens. 24 (7): 447-457.
Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA: Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995, 92 (7): 1954-1968.
Morillo CA, Klein GJ, Jones DL, Guiraudon CM: Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation. 1995, 91 (5): 1588-1595.
Shinagawa K, Shi YF, Tardif JC, Leung TK, Nattel S: Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs. Circulation. 2002, 105 (22): 2672-2678. 10.1161/01.CIR.0000016826.62813.F5.
Boixel C, Fontaine V, Rucker-Martin C, Milliez P, Louedec L, Michel JB, Jacob MP, Hatem SN: Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat. J Am Coll Cardiol. 2003, 42 (2): 336-344. 10.1016/S0735-1097(03)00578-3.
Marin F, Roldan V, Climent V, Garcia A, Marco P, Lip GY: Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1?. Stroke. 2003, 34 (5): 1181-1186. 10.1161/01.STR.0000065431.76788.D9.
Mukherjee R, Herron AR, Lowry AS, Stroud RE, Stroud MR, Wharton JM, Ikonomidis JS, Crumbley AJ, Spinale FG, Gold MR: Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol. 2006, 97 (4): 532-537. 10.1016/j.amjcard.2005.08.073.
Nakano Y, Niida S, Dote K, Takenaka S, Hirao H, Miura F, Ishida M, Shingu T, Sueda T, Yoshizumi M, et al: Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J Am Coll Cardiol. 2004, 43 (5): 818-825. 10.1016/j.jacc.2003.08.060.
Xu J, Cui G, Esmailian F, Plunkett M, Marelli D, Ardehali A, Odim J, Laks H, Sen L: Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation. 2004, 109 (3): 363-368. 10.1161/01.CIR.0000109495.02213.52.
Gramley F, Lorenzen J, Plisiene J, Rakauskas M, Benetis R, Schmid M, Autschbach R, Knackstedt C, Schimpf T, Mischke K, et al: Decreased plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote increased metalloproteinase activity with increasing duration of human atrial fibrillation. J Cardiovasc Electrophysiol. 2007, 18 (10): 1076-1082. 10.1111/j.1540-8167.2007.00906.x.
Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986, 57 (6): 450-458. 10.1016/0002-9149(86)90771-X.
Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB, Castelli WP: Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol. 1987, 59 (9): 956-960. 10.1016/0002-9149(87)91133-7.
Lester SJ, Ryan EW, Schiller NB, Foster E: Best method in clinical practice and in research studies to determine left atrial size. Am J Cardiol. 1999, 84 (7): 829-832. 10.1016/S0002-9149(99)00446-4.
Wang Y, Gutman JM, Heilbron D, Wahr D, Schiller NB: Atrial volume in a normal adult population by two-dimensional echocardiography. Chest. 1984, 86 (4): 595-601. 10.1378/chest.86.4.595.
Pritchett AM, Jacobsen SJ, Mahoney DW, Rodeheffer RJ, Bailey KR, Redfield MM: Left atrial volume as an index of left atrial size: a population-based study. J Am Coll Cardiol. 2003, 41 (6): 1036-1043. 10.1016/S0735-1097(02)02981-9.
Bellet S: Clinical disorders of the heart beat. 1971, Philadelphia,: Lea & Febiger, 3
Aime-Sempe C, Folliguet T, Rucker-Martin C, Krajewska M, Krajewska S, Heimburger M, Aubier M, Mercadier JJ, Reed JC, Hatem SN: Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol. 1999, 34 (5): 1577-1586. 10.1016/S0735-1097(99)00382-4.
Thijssen VL, Ausma J, Liu GS, Allessie MA, van Eys GJ, Borgers M: Structural changes of atrial myocardium during chronic atrial fibrillation. Cardiovasc Pathol. 2000, 9 (1): 17-28. 10.1016/S1054-8807(99)00038-1.
Miyauchi Y, Zhou S, Okuyama Y, Miyauchi M, Hayashi H, Hamabe A, Fishbein MC, Mandel WJ, Chen LS, Chen PS, et al: Altered atrial electrical restitution and heterogeneous sympathetic hyperinnervation in hearts with chronic left ventricular myocardial infarction: implications for atrial fibrillation. Circulation. 2003, 108 (3): 360-366. 10.1161/01.CIR.0000080327.32573.7C.
Tanaka K, Zlochiver S, Vikstrom KL, Yamazaki M, Moreno J, Klos M, Zaitsev AV, Vaidyanathan R, Auerbach DS, Landas S, et al: Spatial distribution of fibrosis governs fibrillation wave dynamics in the posterior left atrium during heart failure. Circ Res. 2007, 101 (8): 839-847. 10.1161/CIRCRESAHA.107.153858.
Ausma J, Wijffels M, Thone F, Wouters L, Allessie M, Borgers M: Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation. 1997, 96 (9): 3157-3163.
Kostin S, Klein G, Szalay Z, Hein S, Bauer EP, Schaper J: Structural correlate of atrial fibrillation in human patients. Cardiovasc Res. 2002, 54 (2): 361-379. 10.1016/S0008-6363(02)00273-0.
Nattel S: New ideas about atrial fibrillation 50 years on. Nature. 2002, 415 (6868): 219-226. 10.1038/415219a.
Shiroshita-Takeshita A, Brundel BJ, Nattel S: Atrial fibrillation: basic mechanisms, remodeling and triggers. J Interv Card Electrophysiol. 2005, 13 (3): 181-193. 10.1007/s10840-005-2362-y.
Nagase H, Visse R, Murphy G: Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006, 69 (3): 562-573. 10.1016/j.cardiores.2005.12.002.
Hoit BD: Matrix metalloproteinases and atrial structural remodeling. J Am Coll Cardiol. 2003, 42 (2): 345-347. 10.1016/S0735-1097(03)00585-0.
Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C, Ansorge S, Klein HU, Lendeckel U: Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol. 2000, 35 (6): 1669-1677. 10.1016/S0735-1097(00)00611-2.
Rouet-Benzineb P, Gontero B, Dreyfus P, Lafuma C: Angiotensin II induces nuclear factor- kappa B activation in cultured neonatal rat cardiomyocytes through protein kinase C signaling pathway. J Mol Cell Cardiol. 2000, 32 (10): 1767-1778. 10.1006/jmcc.2000.1211.
Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K: Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation. 2000, 101 (22): 2612-2617.
Li YY, McTiernan CF, Feldman AM: Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res. 2000, 46 (2): 214-224. 10.1016/S0008-6363(00)00003-1.
Lin CS, Pan CH: Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. Cell Mol Life Sci. 2008, 65 (10): 1489-1508. 10.1007/s00018-008-7408-8.
Chen CL, Huang SK, Lin JL, Lai LP, Lai SC, Liu CW, Chen WC, Wen CH, Lin CS: Upregulation of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases in rapid atrial pacing-induced atrial fibrillation. J Mol Cell Cardiol. 2008, 45 (6): 742-753. 10.1016/j.yjmcc.2008.07.007.
Kallergis EM, Manios EG, Kanoupakis EM, Mavrakis HE, Arfanakis DA, Maliaraki NE, Lathourakis CE, Chlouverakis GI, Vardas PE: Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation: biochemical assessment of collagen type-I turnover. J Am Coll Cardiol. 2008, 52 (3): 211-215. 10.1016/j.jacc.2008.03.045.
Lin JL, Lai LP, Lin CS, Du CC, Wu TJ, Chen SP, Lee WC, Yang PC, Tseng YZ, Lien WP, et al: Electrophysiological mapping and histological examinations of the swine atrium with sustained (> or = 24 h) atrial fibrillation: a suitable animal model for studying human atrial fibrillation. Cardiology. 2003, 99 (2): 78-84. 10.1159/000069728.
Kamalvand K, Tan K, Lloyd G, Gill J, Bucknall C, Sulke N: Alterations in atrial electrophysiology associated with chronic atrial fibrillation in man. Eur Heart J. 1999, 20 (12): 888-895. 10.1053/euhj.1998.1404.
Li D, Fareh S, Leung TK, Nattel S: Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 1999, 100 (1): 87-95.
Mountain DJ, Singh M, Menon B, Singh K: Interleukin-1beta increases expression and activity of matrix metalloproteinase-2 in cardiac microvascular endothelial cells: role of PKCalpha/beta1 and MAPKs. Am J Physiol Cell Physiol. 2007, 292 (2): C867-875.
Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R: Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation. 2002, 106 (12): 1543-1549. 10.1161/01.CIR.0000028818.33488.7B.
Sawicki G, Leon H, Sawicka J, Sariahmetoglu M, Schulze CJ, Scott PG, Szczesna-Cordary D, Schulz R: Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation. 2005, 112 (4): 544-552. 10.1161/CIRCULATIONAHA.104.531616.
Bergman MR, Cheng S, Honbo N, Piacentini L, Karliner JS, Lovett DH: A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers. Biochem J. 2003, 369 (Pt 3): 485-496.
Alfonso-Jaume MA, Bergman MR, Mahimkar R, Cheng S, Jin ZQ, Karliner JS, Lovett DH: Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB. Am J Physiol Heart Circ Physiol. 2006, 291 (4): H1838-1846. 10.1152/ajpheart.00026.2006.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2261/11/77/prepub